NCT04162340|UnknownPhase 1
Loading search results
Sponsor study identifier
interventional
12
1 country
2
Study Start
July 11, 2019
Actual (reported)Primary Completion
October 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
October 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD4 CAR T cells in patients with relapsed and/or refractory T cell lymphoma.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 11, 2019
Actual (reported)November 11, 2019
Actual (reported)November 14, 2019
Actual (reported)October 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
October 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Number of adverse events after CD4 CAR T cells cell infusion
Determine the toxicity profile of CD4 CAR T cell therapy
2 years particularly the first 28 days after infusion
Incidence of treatment-emergent adverse events
up to 6 months
Disease Free Survival (DFS)
up to 2 years
Progression-Free Survival (PFS)
up to 2 years
Overall Survival (OS)
up to 2 years
Dose escalation phase: CD4 CAR T cells transduced with a lentiviral vector to express CD4 chimeric receptor domain on T cells with an escalation approach, 2e6 to 5e6 CAR-T cells/kg
CD4 CAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Chengdu Military General Hospital
Chengdu, Sichuan, China
Hongyu Zhang, MD/PhD
Peking University Shenzhen Hospital, China
Fang Liu, MD/PhD
Chengdu Military Hospital
First Submitted
November 11, 2019
First Posted
November 14, 2019
Study Start
July 11, 2019
Actual (reported)Primary Completion
Contact the study team to confirm eligibility.
October 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
October 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
May 19, 2021
Record last verified: 2021-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: